Low dose soft X-ray-controlled deep-tissue long-lasting NO release of persistent luminescence nanoplatform for gas-sensitized anticancer therapy

Zhenluan Xue, Mingyang Jiang, Hongrong Liu, Songjun Zeng, Jianhua Hao

Research output: Journal article publicationJournal articleAcademic researchpeer-review

19 Citations (Scopus)

Abstract

Nitric oxide (NO)-based gas therapy is emerged as a new adjunct anti-tumor treatment method, which has triggered a great research interest. Nevertheless, due to the short half-life of NO gas in vivo, it is of significance to develop NO-gas based gasotransmitter with controllable NO release for deep-tissue anti-tumor therapy. Herein, a novel soft X-ray activated persistent luminescence nanotransducer is designed for controllable and long-lasting NO release and deep-tissue anti-cancer therapy by integrating ZnGa2O4:Mn (ZGO:Mn) nanoparticles with light-responsive NO donor (RBS). With the merits of the ultra-low dosage (down to 0.9 mGy) soft X-ray activated persistent luminescence from small sized ZGO:Mn, continuous NO release is achieved for about 40 min after stopping the irradiation of X-ray. Moreover, the green persistent luminescence can be renewably activated by in-situ soft X-ray irradiation, leading to the repeatable long-lasting NO release in deep tissue (up to 24 mm). And the designed NO-releasing platform presents efficient in vitro and in vivo anti-cancer therapy. Therefore, the designed persistent luminescence-based NO gasotransmitter provides a new NO-releasing strategy for depth-independent gas-sensitized therapeutic applications.

Original languageEnglish
Article number120384
JournalBiomaterials
Volume263
DOIs
Publication statusPublished - Dec 2020

Keywords

  • Deep tissue
  • Gas-based tumor therapy
  • NO release
  • Persistent luminescence
  • Ultralow dose X-ray

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Fingerprint

Dive into the research topics of 'Low dose soft X-ray-controlled deep-tissue long-lasting NO release of persistent luminescence nanoplatform for gas-sensitized anticancer therapy'. Together they form a unique fingerprint.

Cite this